These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 26083014)
1. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia. Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014 [TBL] [Abstract][Full Text] [Related]
2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333 [TBL] [Abstract][Full Text] [Related]
3. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]. Xie XT; Jiang SY; Li BS; Yang LL Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730 [TBL] [Abstract][Full Text] [Related]
4. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine. Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162 [TBL] [Abstract][Full Text] [Related]
6. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase. Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772 [TBL] [Abstract][Full Text] [Related]
7. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976 [TBL] [Abstract][Full Text] [Related]
8. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222 [TBL] [Abstract][Full Text] [Related]
10. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171 [TBL] [Abstract][Full Text] [Related]
11. Potential mechanisms of resistance to cytarabine in AML patients. Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078 [TBL] [Abstract][Full Text] [Related]
13. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia. Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267 [TBL] [Abstract][Full Text] [Related]
14. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316 [TBL] [Abstract][Full Text] [Related]
15. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia. Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143 [TBL] [Abstract][Full Text] [Related]
16. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Abraham A; Varatharajan S; Abbas S; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P Pharmacogenomics; 2012 Feb; 13(3):269-82. PubMed ID: 22304580 [TBL] [Abstract][Full Text] [Related]
18. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia. Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985 [TBL] [Abstract][Full Text] [Related]
19. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Galmarini CM; Thomas X; Calvo F; Rousselot P; Rabilloud M; El Jaffari A; Cros E; Dumontet C Br J Haematol; 2002 Jun; 117(4):860-8. PubMed ID: 12060121 [TBL] [Abstract][Full Text] [Related]
20. Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia. Medina-Sanson A; Ramírez-Pacheco A; Moreno-Guerrero SS; Dorantes-Acosta EM; Sánchez-Preza M; Reyes-López A Biomed Res Int; 2015; 2015():309491. PubMed ID: 26090398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]